Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Bio Preventive Medicine Corp., a biotechnology firm currently in the clinical development phase, specializes in the proactive identification and mitigation of various illnesses. The company develops comprehensive strategies for the prevention, screening, and ongoing oversight of chronic conditions and cancer treatment. A key offering is the DNlite test, a suite of proprietary and medically validated non-intrusive urine analyses designed to aid in the management of diabetic kidney disease, encompassing specific products like DNlite-IVD103 and DNlite-DN_Score. Established in 2014, its main operations are located in Zhubei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.